Asthma Clinical Trials in Beijing
10 recruitingBeijing, China
Showing 1–10 of 10 trials
Recruiting
Phase 3
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
Eosinophilic Asthma
AstraZeneca400 enrolled157 locationsNCT06750289
Recruiting
Phase 3
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Severe Asthma
AstraZeneca400 enrolled75 locationsNCT07363642
Recruiting
Phase 3
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
Asthma
AstraZeneca790 enrolled101 locationsNCT06471257
Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
Asthma
AstraZeneca355 enrolled21 locationsNCT06419413
Recruiting
Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
Eli Lilly and Company531 enrolled121 locationsNCT07219173
Recruiting
Phase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Asthma
AstraZeneca440 enrolled131 locationsNCT06307665
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
Asthma
AstraZeneca231 enrolled142 locationsNCT06023589
Recruiting
Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Asthma
Sanofi1,324 enrolled250 locationsNCT05097287
Recruiting
Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Asthma
Sanofi1,147 enrolled240 locationsNCT06676319
Recruiting
Phase 2
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
Asthma
Sanofi900 enrolled114 locationsNCT06609239